Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...

An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs.

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...

Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...

The Alliance for Pharmacy Compounding rebutted Novo's FDA petition to bar compounding pharmacies from copying its weight loss ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

Ozempic and similar drugs for Type 2 diabetes and weight loss are in such ... Novo Nordisk and Eli Lilly are moving to end ...

GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects. Novo Nordisk, Eli Lilly ...